VENCF (Vencanna Ventures) Moat Score: 2/10 (As of Jun. 29, 2026)


What is Vencanna Ventures Moat Score?

Vencanna Ventures VENCF +80.00% Moat Score is 2 as of Jun. 29, 2026. The stock has 4 warning signs investors should review. Among 1,030 Drug Manufacturers companies, Vencanna Ventures ranks better than 81.65% on this metric.

Vencanna Ventures has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Vencanna Ventures has No Moat: Vencanna Ventures Inc operates in a highly competitive cannabis market with low barriers to entry and lacks significant intellectual property or brand strength, resulting in a very weak competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Vencanna Ventures might have No Moat - Very weak/transient advantages.

Vencanna Ventures  (OTCPK:VENCF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Vencanna Ventures Moat Score Related Terms

VENCF vs ZTS, UTHR: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Vencanna Ventures's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vencanna Ventures Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vencanna Ventures's Moat Score distribution charts can be found below:

* The bar in red indicates where Vencanna Ventures's Moat Score falls into.


Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Vencanna Ventures (VENCF) has a Moat Score of 2 as of Jun. 29, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Vencanna Ventures ranks #189 out of 1030 companies in the Drug Manufacturers industry, placing it in the top 18.3%.
Is Vencanna Ventures' Moat Score too high?
Vencanna Ventures' current Moat Score is 2. Based on the distribution chart, Vencanna Ventures ranks #189 out of 1030 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Vencanna Ventures' Moat Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vencanna Ventures ranks #189 out of 1030 companies for Moat Score. This places Vencanna Ventures in the top 18% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Vencanna Ventures's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vencanna Ventures stock overvalued right now?
Vencanna Ventures (VENCF) has a current Moat Score of 2. The current Moat Score is 2. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Vencanna Ventures (VENCF), the current Moat Score is 2 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vencanna Ventures Business Description

Other Exchanges VENI:Canada
Address 622 5th Avenue SW, Suite 200, Calgary, AB, CAN, T2P 0M6
Vencanna Ventures Inc aims to provide investors with a diversified, high-growth, cannabis investment plan through strategic investments and acquisitions focused throughout the value chain (cultivation, processing, and distribution), including ancillary businesses. The company generates the majority of its revenue from the United States.